Patanjali's Apology to Supreme Court: Baba Ramdev and Acharya Balkrishna Address Misleading Advertisements

In their affidavits submitted to the highest judicial body, the pair expressed their unwavering commitment to uphold the sanctity of law and justice. They pledged to refrain from making any public statements that could contravene the assurances previously provided to the Supreme Court in November of the preceding year.

Baba Ramdev and Acharya Balkrishna, the Managing Director of Patanjali Ayurved, have issued a sincere and unequivocal apology before the Supreme Court following a contempt notice served to their company due to the persistent dissemination of misleading advertisements.

In their affidavits submitted to the highest judicial body, the pair expressed their unwavering commitment to uphold the sanctity of law and justice. They pledged to refrain from making any public statements that could contravene the assurances previously provided to the Supreme Court in November of the preceding year.

Advertisement

Earlier, Patanjali had assured the apex court that it would abstain from making casual assertions regarding the medicinal properties of its products. Furthermore, the company vowed not to advertise or endorse its products in a manner that violates legal provisions. It also committed to refraining from issuing any statements disparaging any system of medicine through media channels.

During the prior hearing, a bench comprising Justices Hima Kohli and Ahsanuddin Amanullah dismissed Patanjali’s claim that its media department was unaware of the Supreme Court's directives. Ramdev and Balkrishna were admonished for submitting improper versions of affidavits and were instructed to appear personally on the subsequent hearing date.

Advertisement

Their appearance was mandated as Patanjali had failed to respond to the contempt notice issued by the apex court.

The Indian Medical Association has urged for action against Patanjali for violating the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954. This legislation prohibits the advertisement of certain products for the treatment of specific diseases and disorders, including but not limited to diabetes, heart diseases, high or low blood pressure, and obesity.

Advertisement

Read also | Record-Breaking Surge: Sensex Hits Historic 75,000-Mark, Nifty Peaks to New Heights

Read also | VilCart Hits Milestone: Surpasses Rs 100 Crore Revenue in March

Advertisement

Advertisement